본문 바로가기
KERD
논문KCI 등재

알레르기 면역요법

송태원|김선태|김세훈|이현희|손성욱|김상하|이용원|박중원|김태범|한만용|김우경|남동호|허규영
대한천식알레르기학회 (The Korean Academy of Asthma, Allergy and Clinical Immunology)|2010.09|천식 및 알레르기|제30권 제3호|pp. 153-183

2

조회

0

다운로드

9

인용

0

참고문헌

주제분류임상병리학

참고문헌 (202)

  1. Hur GY, "Surveillance of allergy immunotherapy", Korean J Asthma Allergy Clin Immunol, 29, pp.730~6 (2009)
  2. Till SJ, "Immunological responses to allergen immunotherapy", Clin Allergy Immunol, 18, pp.85~104 (2004)
  3. Till SJ, "Mechanisms of immunotherapy", J Allergy Clin Immunol, 113, pp.1025~34 (2004)
  4. Durham SR, "Grass pollen immunotherapy inhibits allergen - induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma", J Allergy Clin Immunol, 97, pp.1356~65 (1996)
  5. Evans R, "The effect of immunotherapy on humoral and cellular responses in ragweed hayfever", J Clin Invest, 57, pp.1378~85 (1976)
  6. Hamid QA, "Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy", J Allergy Clin Immunol, 99, pp.254~60 (1997)
  7. Tulic MK, "Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response", J Allergy Clin Immunol, 113, pp.235~41 (2004)
  8. Bellinghausen I, "Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects", Eur J Immunol, 27, pp.1131~9 (1997)
  9. Francis JN, "Induction of IL-10+ CD4+CD25+ T cells by grass pollen immunotherapy", J Allergy Clin Immunol, 111, pp.1255~61 (2003)
  10. Jutel M, "IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy", Eur J Immunol, 33, pp.1205~14 (2003)
  11. Savolainen J, "Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy", Clin Exp Allergy, 34, pp.413~9 (2004)
  12. Durham SR, "Grass pollen immunotherapy decreases the number of mast cells in the skin", Clin Exp Allergy, 29, pp.1490~6 (1999)
  13. Moingeon P, "Immune mechanisms of allergen-specific sublingual immunotherapy", Allergy, 61, pp.151~65 (2006)
  14. Bousquet J, "Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy", Ann Allergy, 56, pp.456~459 (1986)
  15. Gleich GJ, "Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study", J Allergy Clin Immunol, 70, pp.261~271 (1982)
  16. Lichtenstein LM, "IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy", J Clin Invest, 52, pp.472~482 (1973)
  17. Creticos PS, "Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy", J Clin Invest, 76, pp.2247~2253 (1985)
  18. Rak S, "The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients", J Allergy Clin Immunol, 82, pp.470~480 (1988)
  19. Sadan N, "Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement", N Engl J Med, 280, pp.623~627 (1969)
  20. Ewan PW, "Venomspecific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings", Clin Exp Allergy, 23, pp.647~60 (1993)
  21. Djurup R, "High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens", Clin Allergy, 17, pp.459~68 (1987)
  22. Michils A, "Early effect of ultrarush venom immunotherapy on the IgG antibody response", Allergy, 55, pp.455~62 (2000)
  23. Michils A, "Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression", J Allergy Clin Immunol, 102, pp.118~26 (1998)
  24. Wachholz PA, "Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy", J Allergy Clin Immunol, 112, pp.915~22 (2003)
  25. Cantani A, "A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma", J Investig Allergol Clin Immunol, 7, pp.90~7 (1997)
  26. Ross RN, "Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebocontrolled studies", Clin Ther, 22, pp.342~50 (2000)
  27. Abramson MJ, "Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials", Am J Respir Crit Care Med, 151, pp.969~74 (1995)
  28. Ross RN, "Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis", Clin Ther, 22, pp.351~8 (2000)
  29. Ariano R, "Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized,. controlled trial", Allergy, 54, pp.313~9 (1999)
  30. Malling HJ, "Diagnosis and immunotherapy of mould allergy. VII. IgG subclass response and relation to the clinical efficacy of immunotherapy with Cladosporium", Allergy, 43, pp.60~70 (1988)
  31. Alvarez-Cuesta E, "Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a doubleblind placebo study", J Allergy Clin Immunol, 93, pp.556~566 (1994)
  32. Aas K, "Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust", Acta Paediatr Scand, 60, pp.264~8 (1971)
  33. Kang BC, "The role of immunotherapy in cockroach asthma", J Asthma, 25, pp.205~18 (1988)
  34. Portnoy JM, "Immunotherapy for asthma: unfavorable studies", Ann Allergy Asthma Immunol, 87, pp.28~32 (2001)
  35. Abramson MJ, "Allergen immunotherapy for asthma", Cochrane Database Syst Rev (2003)
  36. Jacobsen L, "Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up", Allergy, 52, pp.914~20 (1997)
  37. Johnstone DE, "The value of hyposensitization therapy for bronchial asthma in children--a 14-year study", Pediatrics, 42, pp.793~802 (1968)
  38. Pajno GB, "Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study", Clin Exp Allergy, 31, pp.1392~7 (2001)
  39. Sampson HA, "Food anaphylaxis", Br Med Bull, 56, pp.925~35 (2000)
  40. Nelson HS, "Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract", J Allergy Clin Immunol, 99, pp.744~51 (1997)
  41. Enrique E, "Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract", J Allergy Clin Immunol, 116, pp.1073~9 (2005)
  42. Werfel T, "Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi- centre, randomized, dose-response study", Allergy, 61, pp.202~5 (2006)
  43. Nahm DH, "Treatment of atopic dermatitis with a combination of allergenspecific immunotherapy and a histamine-immunoglobulin complex", Int Arch Allergy Immunol, 146, pp.235~40 (2008)
  44. Pajno GB, "Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study", J Allergy Clin Immunol, 120, pp.164~70 (2007)
  45. Bucher X, "Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut", Allergy, 59, pp.1272~6 (2004)
  46. Hansen KS, "Food allergy to apple and specific immunotherapy with birch pollen", Mol Nutr Food Res, 48, pp.441~448 (2004)
  47. Asero R, "Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients", Clin Exp Allergy, 28, pp.1368~73 (1998)
  48. 이근호, "면역치료로 치유된 구강 알레르기 증후군 1예", 천식 및 알레르기, 25(2), pp.150~152 (2005), 대한천식알레르기학회
  49. Bousquet J, "Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment", J Allergy Clin Immunol, 76, pp.734~44 (1985)
  50. "National Guideline for the Management of Asthma", Korean Asthma Allergy Clin Immunol, 18, pp.339~84 (1998)
  51. Joint Task Force on Practice Parameters, "Allergen immunotherapy: a practice parameter second update", J Allergy Clin Immunol, 120, pp.S25~85 (2007)
  52. Wallace DV, "The diagnosis and management of rhinitis: an updated practice parameter", J Allergy Clin Immunol, 122, pp.1~84 (2008)
  53. Penagos M, "Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials", Ann Allergy Asthma Immunol, 97, pp.141~8 (2006)
  54. Canonica GW, "Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009", Allergy, 64(Suppl 91), pp.1~59 (2009)
  55. Bousquet J, "Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)", Allergy, 63(Suppl 86), pp.8~160 (2008)
  56. Lim SB, "Study on allergen of immunotherapy in allergic diseases", Korean J Asthma Allergy Clin Immunol, 8, pp.139~49 (1988)
  57. Park HS, "Allergen standardization of dermatophagoides farinae extracts", Korean J Asthma Allergy Clin Immunol, 16, pp.19~25 (1996)
  58. Frew AJ, "Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment- resistant seasonal allergic rhinoconjunctivitis", J Allergy Clin Immunol, 117, pp.319~25 (2006)
  59. Chapman MD, "The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines", J Allergy Clin Immunol, 122, pp.882~9 (2008)
  60. Adkinson NF Jr, "A controlled trial of immunotherapy for asthma in allergic children", N Engl J Med, 336, pp.324~31 (1997)
  61. 김태범, "흡입 알레르겐에 대한 감작율: 다기관 공동연구", 천식 및 알레르기, 23(3), pp.483~493 (2003), 대한천식알레르기학회
  62. 허규영, "집먼지진드기 면역요법 후 천식이 소실된 성인 천식 환자들의 임상적 특성", 천식 및 알레르기, 27(4), pp.257~262 (2007), 대한천식알레르기학회
  63. 오재원, "대기 중 알레르기 화분(꽃가루) 농도 예보제 개발", 대한의사협회지, 52(6), pp.579~591 (2009), 대한의사협회
  64. Ewbank PA, "A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract", J Allergy Clin Immunol, 111, pp.115~61 (2003)
  65. Lent AM, "Immunologic response to administration of standardized dog allergen extract at differing doses", J Allergy Clin Immunol, 118, pp.1249~56 (2006)
  66. Creticos PS, "Responses to ragweed-pollen nasal challenge before and after immunotherapy", J Allergy Clin Immunol, 84, pp.197~205 (1989)
  67. Horst M, "Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract", J Allergy Clin Immunol, 85, pp.460~72 (1990)
  68. Malling HJ, "Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum", Allergy, 41, pp.507~19 (1986)
  69. Haugaard L, , J Allergy Clin Immunol, 91, pp.709~22 (1993)
  70. Kordash TR, "Effect of mixing allergenic extracts containing Helminthosporium, D. farinae, and cockroach with perennial ryegrass", Ann Allergy, 71, pp.240~6 (1993)
  71. Bodtger U, "The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study", Allergy, 57, pp.297~305 (2002)
  72. Pence HL, "Immunotherapy for mountain cedar pollinosis. A double-blind controlled study", J Allergy Clin Immunol, 58, pp.39~50 (1976)
  73. Lee YW, "Cross-allergenicity of pollens from the Compositae family: Artemisia vulgaris, Dendranthema grandiflorum, and Taraxacum officinale", Ann Allergy Asthma Immunol, 99, pp.526~33 (2007)
  74. Leavengood DC, "Cross allergenicity among grasses determined by tissue threshold changes", J Allergy Clin Immunol, 76, pp.789~94 (1985)
  75. Nelson HS, "Studies of allergen extract stability: the effects of dilution and mixing", J Allergy Clin Immunol, 98, pp.382~8 (1996)
  76. Grier TJ, "Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts", Ann Allergy Asthma Immunol, 99, pp.151~60 (2007)
  77. Anderson MC, "Antigenic and allergenic changes during storage of a pollen extract", J Allergy Clin Immunol, 69, pp.3~10 (1982)
  78. Sridhara S, "A study on antigenic and allergenic changes during storage in three different biological extracts", Asian Pac J Allergy Immunol, 10, pp.33~8 (1992)
  79. Tipton WR, "Experience with daily immunotherapy in 59 adult allergic patients", J Allergy Clin Immunol, 69, pp.194~9 (1982)
  80. Amin HS, "Evaluation of near-fatal reactions to allergen immunotherapy injections", J Allergy Clin Immunol, 117, pp.169~75 (2006)
  81. Cox L, "Accelerated immunotherapy schedules: review of efficacy and safety", Ann Allergy Asthma Immunol, 97, pp.126~37 (2006)
  82. Nielsen L, "Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study", J Allergy Clin Immunol, 97, pp.1207~13 (1996)
  83. Sharkey P, "Rush immunotherapy: experience with a one-day schedule", Ann Allergy Asthma Immunol, 76, pp.175~80 (1996)
  84. Portnoy J, "Incidence of systemic reactions during rush immunotherapy", Ann Allergy, 68, pp.493~8 (1992)
  85. Roll A, "Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy", J Investig Allergol Clin Immunol, 16, pp.79~85 (2006)
  86. Tabar AI, "Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy", J Investig Allergol Clin Immunol, 9, pp.155~64 (1999)
  87. Kohno Y, "Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma", J Allergy Clin Immunol, 102, pp.927~34 (1998)
  88. Portnoy J, "Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts", Ann Allergy, 73, pp.409~18 (1994)
  89. Ohashi Y, "Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis", Ann Allergy Asthma Immunol, 96, pp.600~5 (2006)
  90. Casale TB, "Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis", J Allergy Clin Immunol, 117, pp.134~40 (2006)
  91. Des Roches A, "Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation", Allergy, 51, pp.430~3 (1996)
  92. Kanter LJ, "Needle sticks and adverse outcomes in office-based allergy practices", Ann Allergy Asthma Immunol, 90, pp.389~92 (2003)
  93. "Position statement on the administration of immunotherapy outside of the prescribing allergist facility. Drugs and Anaphylaxis Committee of the American College of Allergy, Asthma and Immunology", Ann Allergy Asthma Immunol, 81, pp.101~102 (1998)
  94. Blazowski L, "Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose", Allergy, 63, pp.374~ (2008)
  95. Lombardi C, "The safety of sublingual immunotherapy with one or more allergens in adults", Allergy, 63, pp.375~6 (2008)
  96. Tankersley MS, "Local reactions during allergen immunotherapy do not require dose adjustment", J Allergy Clin Immunol, 106, pp.840~3 (2000)
  97. Roy SR, "Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy", Ann Allergy Asthma Immunol, 99, pp.82~6 (2007)
  98. Lockey RF, "Systemic reactions and fatalities associated with allergen immunotherapy", Ann Allergy Asthma Immunol, 87, pp.47~55 (2001)
  99. Malling HJ, "Minimising the risks of allergen-specific injection immunotherapy", Drug Saf, 23, pp.323~32 (2000)
  100. Bernstein DI, "Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001", J Allergy Clin Immunol, 113, pp.1129~36 (2004)
  101. Lockey RF, "Fatalities from immunotherapy (IT) and skin testing (ST)", J Allergy Clin Immunol, 79, pp.660~677 (1987)
  102. Bousquet J, "Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma", J Allergy Clin Immunol, 83, pp.797~802 (1989)
  103. Reid MJ, "Survey of fatalities from skin testing and immunotherapy 1985-1989", J Allergy Clin Immunol, 92, pp.6~15 (1993)
  104. Greenberg MA, "Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy", J Allergy Clin Immunol, 77, pp.865~70 (1986)
  105. Matloff SM, "Systemic reactions to immunotherapy", Allergy Proc, 14, pp.347~50 (1993)
  106. Javeed N, "Refractory anaphylactoid shock potentiated by beta-blockers", Cathet Cardiovasc Diagn, 39, pp.383~4 (1996)
  107. Jacobs RL, "Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade", J Allergy Clin Immunol, 68, pp.125~7 (1981)
  108. Toogood JH, "Risk of anaphylaxis in patients receiving betablocker drugs", J Allergy Clin Immunol, 81, pp.1~5 (1998)
  109. Lang DM, "Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both beta-blocker exposure and cardiovascular disorders", Arch Intern Med, 153, pp.2033~40 (1993)
  110. Lang DM, "Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma", Ann Intern Med, 115, pp.270~6 (1991)
  111. Hepner MJ, "Sears-Ewald D, Brown EB. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections", J Allergy Clin Immunol, 86, pp.407~11 (1990)
  112. Muller UR, "Use of beta-blockers during immunotherapy for Hymenoptera venom allergy", J Allergy Clin Immunol, 115, pp.606~10 (2005)
  113. Sherman MS, "A bronchodilator action of glucagon", J Allergy Clin Immunol, 81, pp.908~11 (1988)
  114. Thomas M, "Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers", Emerg Med J, 22, pp.272~3 (2005)
  115. Joint Task Force on Practice Parameters, "The diagnosis and management of anaphylaxis; an updated practice parameter", J Allergy Clin Immunol, 115, pp.S483~523 (2005)
  116. Pumphrey RS, "Lessons for management of anaphylaxis from a study of fatal reactions", Clin Exp Allergy, 30, pp.1144~50 (2000)
  117. Windom HH, "An update on the safety of specific immunotherapy", Curr Opin Allergy Clin Immunol, 8, pp.571~6 (2008)
  118. Cevit O, "Specific allergen immunotherapy: effect on immunologic markers and clinical parameters in asthmatic children", J Investig Allergol Clin Immunol, 17, pp.286~91 (2007)
  119. Pipet A, "Allergenspecific immunotherapy in allergic rhinitis and asthma", Mechanisms and proof of efficacy. Respir Med, 103, pp.80~12 (2009)
  120. Cox L, "Allergen immunotherapy and asthma: efficacy, safety, and other considerations", Allergy Asthma Proc, 29, pp.580~9 (2008)
  121. Garcia-Robaina JC, "Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study", J Allergy Clin Immunol, 118, pp.1026~32 (2006)
  122. Nelson HS, "Multiallergen immunotherapy for allergic rhinitis and asthma", J Allergy Clin Immunol, 123, pp.763~9 (2009)
  123. Ferrer A, "Significant improvement in symptoms,skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae", J Investig Allergol Clin Immunol, 13, pp.244~51 (2003)
  124. Ibero M, "Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus", J Investig Allergol Clin Immunol, 16, pp.194~202 (2006)
  125. Cox L, "Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations", Curr Allergy Asthma Rep, 7, pp.410~20 (2007)
  126. Mohapatra SS, "Immunotherapy for allergies and asthma: present and future", Curr Opin Pharmacol, 10, pp.276~88 (2010)
  127. Boquete M, "Preventive immunotherapy", Allergol Immunopathol, 28, pp.89~93 (2008)
  128. Bertelsen A, "Immunotherapy with dog and cat extracts in children", Allergy, 44, pp.330~5 (1989)
  129. Karlsson R, "A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. II", In vitro results. Allergy, 41, pp.141~50 (1986)
  130. Rosenstreich DL, "The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma", N Engl J Med, 336, pp.1356~63 (1997)
  131. Cools M, "Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen", Allergy, 55, pp.69~73 (2000)
  132. Hedlin G, "Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy", J Allergy Clin Immunol, 103, pp.609~14 (1999)
  133. Cantani A, "Is specific immunotherapy safe and effective in children", Eur Rev Med Pharmacol Sci, 4, pp.139~43 (2000)
  134. Eng PA, "Twelveyear follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood", Allergy, 61, pp.198~201 (2006)
  135. Eng PA, "Long-term efficacy of preseasonal grass pollen immunotherapy in children", Allergy, 57, pp.306~12 (2002)
  136. Jacobsen L, "Preventive aspects of immunotherapy: prevention for children at risk of developing asthma", Ann Allergy Asthma Immunol, 87, pp.43~6 (2001)
  137. Niggemann B, "Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children", Allergy, 61, pp.855~9 (2006)
  138. Des Roches A, "Immunotherapy with a standardized Dermatophagoides teronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children", J Allergy Clin Immunol, 99, pp.450~3 (1997)
  139. Ohashi Y, "Serologic study of the working mechanisms of immunotherapy for children with perennial allergic rhinitis", Arch Otolaryngol Head Neck Surg, 124, pp.1337~46 (1998)
  140. Tabar AI, "Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety", Pediatr Allergy Immunol, 19, pp.67~75 (2008)
  141. Roberts G, "Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma", J Allergy Clin Immunol, 117, pp.263~8 (2006)
  142. Purohit A, "Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives", Clin Exp Allergy, 38, pp.1514~25 (2008)
  143. Nieminen K, "Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy", Pediatr Allergy Immunol (2009)
  144. Kyung Won Kim, "Comparison of Allergic Indices in Monosensitized and Polysensitized Patients with Childhood Asthma", Journal of Korean Medical Science, 21(6), pp.1012~1016 (2006), 대한의학회
  145. Stelmach I, "Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen", Clin Exp Allergy, 39, pp.401~8 (2009)
  146. Calamita Z, "Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method", Allergy, 61, pp.1162~72 (2006)
  147. Dahl R, "Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years", J Allergy Clin Immunol, 121, pp.512~8 (2008)
  148. Dahl R, "Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis", J Allergy Clin Immunol, 118, pp.434~40 (2006)
  149. Durham SR, "Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis", J Allergy Clin Immunol, 117, pp.802~9 (2006)
  150. Gauvreau GM, "Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway response", Am J Respir Crit Care Med, 174, pp.15~20 (2006)
  151. Wilson DR, "Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis", Allergy, 60, pp.4~12 (2005)
  152. Nelson HS, "A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract", J Allergy Clin Immunol, 92, pp.229~36 (1993)
  153. La Rosa M, "Double-blind placebo-controlled evaluation of sublingualswallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis", J Allergy Clin Immunol, 104, pp.425~32 (1999)
  154. Passalacqua G, "Clinical and immunologic effects of a rush ublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial", J Allergy Clin Immunol, 104, pp.964~8 (1999)
  155. Purello-D'Ambrosio F, "Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both", Allergy, 54, pp.968~73 (1999)
  156. Andre C, "A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship", Int Arch Allergy Immunol, 131, pp.111~8 (2003)
  157. Khinchi MS, "Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study", Allergy, 59, pp.45~53 (2004)
  158. Bernardini R, "Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study", Curr Med Res Opin, 22, pp.1515~22 (2006)
  159. Cistero Bahima A, "Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract", J Investig Allergol Clin Immunol, 14, pp.17~25 (2004)
  160. Marogna M, "Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients", Ann Allergy Asthma Immunol, 98, pp.274~80 (2007)
  161. Passalacqua G, "Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects", Clin Exp Allergy, 35, pp.880~3 (2005)
  162. Bagnasco M, "Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings", J Allergy Clin Immunol, 100, pp.122~9 (1997)
  163. Didier A, "Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis", J Allergy Clin Immunol, 120, pp.1338~45 (2007)
  164. Rossi RE, "A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and", or asthma, 2005, pp.18, 277~85
  165. Tripodi S, "Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children", Int Arch Allergy Immunol, 139, pp.149~52 (2006)
  166. Dahl R, "Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis", Allergy, 61, pp.185~90 (2006)
  167. Kleine-Tebbe J, "Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial", Allergy, 61, pp.181~4 (2006)
  168. Marcucci F, "Dose dependence of immunological response to sublingual immunotherapy", Allergy, 60, pp.952~6 (2005)
  169. Cox LS, "Sublingual immunotherapy: a comprehensive review", J Allergy Clin Immunol, 117, pp.1021~35 (2006)
  170. Di Rienzo V, "Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study", Clin Exp Allergy, 33, pp.206~10 (2003)
  171. Marogna M, "Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term (13-year) retrospective study in real life", Int Arch Allergy Immunol, 142, pp.70~8 (2007)
  172. Bowen T, "Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis", Ann Allergy Asthma Immunol, 93, pp.425~30 (2004)
  173. Fiocchi A, "Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years", Ann Allergy Asthma Immunol, 95, pp.254~8 (2005)
  174. Agostinis F, "Safety of sublingual immunotherapy with a monomeric allergoid in very young children", Allergy, 60, pp.133~ (2005)
  175. Di Rienzo V, "Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients", Allergy, 54, pp.1110~3 (1999)
  176. Antico A, "Anaphylaxis by latex sublingual immunotherapy", Allergy, 61, pp.1236~7 (2006)
  177. Dunsky EH, "Anaphylaxis to sublingual immunotherapy", Allergy, 61, pp.1235~ (2006)
  178. Eifan AO, "Anaphylaxis to multiple pollen allergen sublingual immunotherapy", Allergy, 62, pp.567~8 (2007)
  179. Marogna M, "Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more", Allergy, 59, pp.1205~10 (2004)
  180. Larenas-Linnemann D, "European allergen extract units and potency: review of available information", Ann Allergy Asthma Immunol, 100, pp.137~45 (2008)
  181. Park HS, "Evidence of Hop Japanese pollinosis in Korea: IgE sensitization and identification of allergenic components", J Allergy Clin Immunol, 100, pp.475~9 (1997)
  182. Park JW, "Identification and characterization of the major allergen of the Humulus japonicus pollen", Clin Exp Allergy, 29, pp.1080~6 (1999)
  183. Yun YY, "Anaphylaxis to venom of the Pachycondyla species ant", J Allergy Clin Immunol, 104, pp.879~82 (1999)
  184. Cho YS, "Prevalence of pachycondyla chinensis venom allergy in an ant-infested area in Korea", J Allergy Clin Immunol, 110, pp.54~7 (2002)
  185. Lee EK, "Characterization of the major allergens of Pachycondyla chinensis in ant sting anaphylaxis patients", Clin Exp Allergy, 39, pp.602~7 (2009)
  186. Kim SS, "Anaphylaxis caused by the new ant, Pachycondyla chinensis: demonstration of specific IgE and IgE-binding components", J Allergy Clin Immunol, 107, pp.1095~9 (2001)
  187. Bussmann C, "Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis?", J Allergy Clin Immunol, 118, pp.1292~8 (2006)
  188. Novak N, "Allergen specific immunotherapy for atopic dermatitis", Curr Opin Allergy Clin Immunol, 7, pp.542~6 (2007)
  189. Dehlink E, "Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children", Clin Exp Allergy, 36, pp.32~9 (2006)
  190. Bohle B, "Sublingual immunotherapy induces IL- 10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation", J Allergy Clin Immunol, 120, pp.707~13 (2007)
  191. Durham SR, "Sublingual immunoterapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis", J Allergy Clin Immunol, 117, pp.802~9 (2006)
  192. Calamita Z, "Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method", Allergy, 61, pp.1162~72 (2006)
  193. Nieto A, "Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses", J Allergy Clin Immunol, 124, pp.157~61 (2009)
  194. Canonica GW, "Slublingual immunotherapy WHO position paper 2009", ~ (2009)
  195. Möller G, "Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study)", J Allergy Clin Immunol, 109, pp.251~6 (2002)
  196. Novembre E, "coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis", J Allergy Clin Immunol, 114, pp.851~7 (2004)
  197. Norman PS, "Treatment of cat allergy with T-cell reactive peptides", Am J Respir Crit Care Med, 154, pp.1623~8 (1996)
  198. Verhoef A, "T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity", PLos Med, 2, pp.78~ (2005)
  199. Norman PS, "Studies on allergoids .from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever", J Allergy Clin Immunol, 68, pp.460~70 (1981)
  200. Corrigan CJ, "Efficacy and safety of preseasonally-specific immunotherapy with an aluminum- adsorbed six-grass pollen allergoid", Allergy, 60, pp.801~7 (2005)
  201. Niederberger V, "Vaccination with genetically engineered allergens prevents progression of allergic disease", Proc Natl Acad Sci USA, 101(Suppl 2), pp.14677~82 (2004)
  202. Creticos PS, "Immunotherpay with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis", N Engl J Med, 355, pp.1445~55 (2006)

관련 논문AI추천

소아천식의 알레르겐 특이 면역요법의 효과오재원대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2005 · 제15권 제1호알레르기비염에서 면역요법의 현재와 미래이재서대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2005 · 제48권 제11호설하면역치료김선태대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2010 · 제21권 제1호알레르기 질환에서 피하면역주사요법과 설하면역요법김선태대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2011 · 제22권 제2호알레르기비염 환자를 대상으로 시행한 면역치료의 부작용김명구, 김성완, 여승근, 은영규, 조중생대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2005 · 제48권 제6호식품 알레르기의 치료안강모대한천식알레르기학회 · 천식 및 알레르기2006 · 제26권 제4호

이 간행물의 다른 논문 (11건)

알레르기질환 및 아토피피부염에서 가려움증의 병인 및 치료적 접근홍승필, 원종현pp. 184-192자가면역성 갑상선질환과 알레르기남동호pp. 193-194그레이브스병 환자에서 알레르기 지표와 갑상선자극호르몬 수용체 항체의 관련성이병훈, 김상훈, 이재형, 안영민, 채정돈, 김효정, 전재석pp. 195-201벌독 아나필락시스 환자에서 과거 벌자상 알레르기반응 병력과 특이 IgE 항체 검사 결과의 분석고영일, 김영일, 박상훈, 윤지희pp. 202-208메밀 알레르기 진단에 있어서 16-kD 및 19-kD 재조합 알레르겐 특이 IgE 측정의 유용성홍천수, 박해심, 신유섭, 이재현, 박중원, 이용원pp. 209-215
원문 보기